Latest news


Second quarter and first half year 2014 results

Posted on Aug 26, 2014

Lysaker, 26 August 2014 – PCI Biotech presented the company’s second quarter and first half year 2014 report 26 August 2014 at 08:00 at Felix Konferansesenter, Oslo. The presentation and Q2 and first half year 2014 report are attached below: Q2 2014 Presentation Q2 2014 Report

Successful completion of the second group in the intra-tumour light dose escalation part of the ENHANCE study

Posted on Aug 22, 2014

Lysaker, 22 August 2014 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the treatment evaluation of the second group in the intra-tumour light dose escalation part of the ENHANCE study has been completed.  ENHANCE is a phase II study of Amphinex® in combination with the cytotoxic agent bleomycin in recurrent head and […]

Presentation of second quarter and first half year 2014 results

Posted on Aug 20, 2014

Lysaker, 19 August 2014 – PCI Biotech invites to a presentation of the company’s second quarter and first half year 2014 report on Tuesday 26 August 2014. The presentation will take place at Felix Konferansesenter at Aker Brygge, Bryggetorget 3, Oslo and will start at 08:00. For further information, please contact: Ronny Skuggedal, CFO Email: rs@pcibiotech.no […]